Skip to main content
RMD Open logoLink to RMD Open
. 2018 Mar 26;4(1):rmdopen-2017-000582corr1. doi: 10.1136/rmdopen-2017-000582corr1

Correction: 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis

PMCID: PMC5869210  PMID: 29595841

van der Heijde D, Deodhar A, FitzGerald O, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open 2018;4:e000582. doi: 10.1136/rmdopen-2017-000582.

Several changes were inadvertently missed during the production stage. These corrections are now incorporated into the current version.


Articles from RMD Open are provided here courtesy of BMJ Publishing Group

RESOURCES